158 related articles for article (PubMed ID: 23069279)
21. RAS, FLT3, and C-KIT mutations in immunophenotyped canine leukemias.
Usher SG; Radford AD; Villiers EJ; Blackwood L
Exp Hematol; 2009 Jan; 37(1):65-77. PubMed ID: 18977066
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors.
Webster JD; Kiupel M; Yuzbasiyan-Gurkan V
BMC Cancer; 2006 Apr; 6():85. PubMed ID: 16579858
[TBL] [Abstract][Full Text] [Related]
23. Absence of gene mutations in KIT-positive thymic epithelial tumors.
Tsuchida M; Umezu H; Hashimoto T; Shinohara H; Koike T; Hosaka Y; Eimoto T; Hayashi JI
Lung Cancer; 2008 Dec; 62(3):321-5. PubMed ID: 18486988
[TBL] [Abstract][Full Text] [Related]
24. KIT-negative gastrointestinal stromal tumor of the abdominal soft tissue: a clinicopathologic and genetic study of 10 cases.
Yamamoto H; Kojima A; Nagata S; Tomita Y; Takahashi S; Oda Y
Am J Surg Pathol; 2011 Sep; 35(9):1287-95. PubMed ID: 21836495
[TBL] [Abstract][Full Text] [Related]
25. Exon 15 BRAF mutations are uncommon in canine oral malignant melanomas.
Shelly S; Chien MB; Yip B; Kent MS; Theon AP; McCallan JL; London CA
Mamm Genome; 2005 Mar; 16(3):211-7. PubMed ID: 15834638
[TBL] [Abstract][Full Text] [Related]
26. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit.
London CA; Galli SJ; Yuuki T; Hu ZQ; Helfand SC; Geissler EN
Exp Hematol; 1999 Apr; 27(4):689-97. PubMed ID: 10210327
[TBL] [Abstract][Full Text] [Related]
27. Aberrant autophosphorylation of c-Kit receptor in canine mast cell tumor cell lines.
Takeuchi Y; Fujino Y; Watanabe M; Nakagawa T; Ohno K; Sasaki N; Sugano S; Tsujimoto H
Vet Immunol Immunopathol; 2010 Oct; 137(3-4):208-16. PubMed ID: 20591500
[TBL] [Abstract][Full Text] [Related]
28. Tandem duplication of KIT exon 11 influences the proteome of canine mast cell tumours.
Schlieben P; Meyer A; Weise C; Bondzio A; Gruber AD; Klopfleisch R
J Comp Pathol; 2013 May; 148(4):318-22. PubMed ID: 22935087
[TBL] [Abstract][Full Text] [Related]
29. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis.
Andersson J; Bümming P; Meis-Kindblom JM; Sihto H; Nupponen N; Joensuu H; Odén A; Gustavsson B; Kindblom LG; Nilsson B
Gastroenterology; 2006 May; 130(6):1573-81. PubMed ID: 16697720
[TBL] [Abstract][Full Text] [Related]
30. Heterogeneity of internal tandem duplications in the c-kit of dogs with multiple mast cell tumours.
Amagai Y; Tanaka A; Matsuda A; Jung K; Oida K; Nishikawa S; Jang H; Matsuda H
J Small Anim Pract; 2013 Jul; 54(7):377-80. PubMed ID: 23614673
[TBL] [Abstract][Full Text] [Related]
31. Lack of correlation between immunohistochemical expression of CKIT and KIT mutations in atypical acral nevi.
Park E; Yang S; Emley A; DeCarlo K; Richards J; Mahalingam M
Am J Dermatopathol; 2012 Feb; 34(1):41-6. PubMed ID: 22094233
[TBL] [Abstract][Full Text] [Related]
32. Somatic activation of KIT in distinct subtypes of melanoma.
Curtin JA; Busam K; Pinkel D; Bastian BC
J Clin Oncol; 2006 Sep; 24(26):4340-6. PubMed ID: 16908931
[TBL] [Abstract][Full Text] [Related]
33. Expression of AP-2alpha, c-kit, and cleaved caspase-6 and -3 in naevi and malignant melanomas of the skin. A possible role for caspases in melanoma progression?
Woenckhaus C; Giebel J; Failing K; Fenic I; Dittberner T; Poetsch M
J Pathol; 2003 Oct; 201(2):278-87. PubMed ID: 14517845
[TBL] [Abstract][Full Text] [Related]
34. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression.
Montone KT; van Belle P; Elenitsas R; Elder DE
Mod Pathol; 1997 Sep; 10(9):939-44. PubMed ID: 9310959
[TBL] [Abstract][Full Text] [Related]
35. KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma.
Holst VA; Marshall CE; Moskaluk CA; Frierson HF
Mod Pathol; 1999 Oct; 12(10):956-60. PubMed ID: 10530560
[TBL] [Abstract][Full Text] [Related]
36. Imatinib elicited a favorable response in a dog with a mast cell tumor carrying a c-kit c.1523A>T mutation via suppression of constitutive KIT activation.
Yamada O; Kobayashi M; Sugisaki O; Ishii N; Ito K; Kuroki S; Sasaki Y; Isotani M; Ono K; Washizu T; Bonkobara M
Vet Immunol Immunopathol; 2011 Jul; 142(1-2):101-6. PubMed ID: 21561667
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of Kit receptor tyrosine kinase dysregulations in feline cutaneous mast cell tumors.
Sabattini S; Guadagni Frizzon M; Gentilini F; Turba ME; Capitani O; Bettini G
Vet Pathol; 2013 Sep; 50(5):797-805. PubMed ID: 23377219
[TBL] [Abstract][Full Text] [Related]
38. Platelet-derived growth factor receptor family mutations in gastrointestinal stromal tumours.
Sihto H; Franssila K; Tanner M; Vasama-Nolvi C; Sarlomo-Rikala M; Nupponen NN; Joensuu H; Isola J
Scand J Gastroenterol; 2006 Jul; 41(7):805-11. PubMed ID: 16785193
[TBL] [Abstract][Full Text] [Related]
39. KIT mutations in ocular melanoma: frequency and anatomic distribution.
Wallander ML; Layfield LJ; Emerson LL; Mamalis N; Davis D; Tripp SR; Holden JA
Mod Pathol; 2011 Aug; 24(8):1031-5. PubMed ID: 21478825
[TBL] [Abstract][Full Text] [Related]
40. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type.
Torres-Cabala CA; Wang WL; Trent J; Yang D; Chen S; Galbincea J; Kim KB; Woodman S; Davies M; Plaza JA; Nash JW; Prieto VG; Lazar AJ; Ivan D
Mod Pathol; 2009 Nov; 22(11):1446-56. PubMed ID: 19718013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
